Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Clinical trial NCT00324155 · COMPLETED
Trial details
- NCT number
- NCT00324155
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2006-08-01
- Primary completion
- 2011-01-01
- Enrollment
- 681
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.